Coherus BioSciences’ (CHRS) Buy Rating Reiterated at HC Wainwright
HC Wainwright reissued their buy rating on shares of Coherus BioSciences (NASDAQ:CHRS – Free Report) in a research report report published on Tuesday morning,Benzinga reports. They currently have a $7.00 price target on the biotechnology company’s stock. Several other equities research analysts have also recently commented on the company. UBS Group reissued a “neutral” rating […]
More Stories
Top 10 Investment Accounting Software & Other Related Software
Managing complex investment portfolios can be hectic most of the time, as a small mistake can lead to a huge...
Top 10 Richest K-Pop Idols in 2026
Do you also like K-pop or Korean pop? Then this article is for you. Let’s start. In this blog, you...
Over-the-Counter Medicines, Other Items Recalled Over Feces Contamination: FDA
By Jack Phillips The U.S. Food and Drug Administration (FDA) late last week announced that a distributor is recalling its...
Iranian President Says His Country in ‘Full-Fledged War’ With US, Europe, and Israel
By Jack Phillips Iranian President Masoud Pezeshkian said Saturday that the Iranian regime is in a full-scale war with the...
US Airline Industry Caps a Strong 2025—What Lies Ahead in 2026
By Panos Mourdoukoutas Despite a shaky start earlier in the year, U.S. airline travel reached another milestone during the 2025...
What Trump’s National Security Strategy Means for Canada
By Noe Chartier Canada receives but a passing mention in the recently released U.S. National Security Strategy, but that doesn’t...